Claudia Trojaniello

Statistics

Publications

Citations

769

H-Index

Active since

2016

Affiliations

Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"(Current)

Istituti di Ricovero e Cura a Carattere Scientifico

Assistance Publique – Hôpitaux de Paris

Royal North Shore Hospital

The University of Sydney

Claudia Trojaniello is an author at Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" specializing in oncology, immunotherapy, and cancer immunotherapy.

ORCID

Publications per year

2016–2024

Publications

Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study

Inês Pires da Silva, Tasnia Ahmed, Irene L. M. Reijers et al. · The Lancet Oncology · 2021 · 215 citations

Medicine, Oncology, Pharmacotherapy +16

Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

Maria Carmela Piccirillo, Paolo A. Ascierto, Carlo Salvarani et al. · Journal of Translational Medicine · 2020 · 112 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +15

Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma

Alice Baggi, Pietro Quaglino, Marco Rubatto et al. · European Journal of Cancer · 2021 · 107 citations

Medicine, Dermatology, Oncology +14

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Vincenzo Montesarchio, Roberto Parella, Chiara Iommelli et al. · Journal for ImmunoTherapy of Cancer · 2020 · 90 citations · Full text

Veterinary Medicine, Immunology, Pharmacotherapy +17

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis

Prachi Bhave, Lalit Pallan, Georgina V. Long et al. · British Journal of Cancer · 2020 · 63 citations · Full text

Pharmacy, Immunology, Oncology +17

1–5 of 14